|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Atherosclerosis | |||||
| 2 | More general conditions related to this trial | ||||
| Arterial Occlusive Diseases | |||||
| Arteriosclerosis | |||||
| Cardiovascular Diseases | |||||
| Vascular Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| 17B-estradiol | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Estradiol | |||||
| Estradiol 17 beta-cypionate | |||||
| Estradiol 3-benzoate | |||||
| Estradiol valerate | |||||
| Polyestradiol phosphate | |||||
| 5 | More general drug interventions related to this trial | ||||
| Contraceptive Agents | |||||
| Contraceptive Agents, Female | |||||
| Estrogens | |||||
| Hormones | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Reproductive Control Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute on Aging (NIA) | |||||